{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:11:56Z","timestamp":1790424716474,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7077","license":[{"start":{"date-parts":[[2005,12,11]],"date-time":"2005-12-11T00:00:00Z","timestamp":1134259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2005,12,11]],"date-time":"2005-12-11T00:00:00Z","timestamp":1134259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2006,2,9]]},"DOI":"10.1038\/nature04295","type":"journal-article","created":{"date-parts":[[2005,12,11]],"date-time":"2005-12-11T13:14:08Z","timestamp":1134306848000},"page":"745-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":200,"title":["Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection"],"prefix":"10.1038","volume":"439","author":[{"given":"Koert J.","family":"Stittelaar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieve","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"van Amerongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob F.","family":"van Lavieren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Hol\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Niesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G. H.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben A. M.","family":"van der Zeijst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D. M. E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,12,11]]},"reference":[{"key":"BFnature04295_CR1","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1038\/labinvest.3780373","volume":"81","author":"GM Zaucha","year":"2001","unstructured":"Zaucha, G. M., Jahrling, P. B., Geisbert, T. W., Swearengen, J. R. & Hensley, L. The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 81, 1581\u20131600 (2001)","journal-title":"Lab. Invest."},{"key":"BFnature04295_CR2","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","volume":"79","author":"KJ Stittelaar","year":"2005","unstructured":"Stittelaar, K. J. et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J. Virol. 79, 7845\u20137851 (2005)","journal-title":"J. Virol."},{"key":"BFnature04295_CR3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nri845","volume":"2","author":"GL Smith","year":"2002","unstructured":"Smith, G. L. & McFadden, G. Smallpox: anything to declare? Nature Rev. Immunol. 2, 521\u2013527 (2002)","journal-title":"Nature Rev. Immunol."},{"key":"BFnature04295_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJM198011273032204","volume":"303","author":"JG Breman","year":"1980","unstructured":"Breman, J. G. & Arita, I. The confirmation and maintenance of smallpox eradication. N. Engl. J. Med. 303, 1263\u20131273 (1980)","journal-title":"N. Engl. J. Med."},{"key":"BFnature04295_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00001432-200404000-00003","volume":"17","author":"S Lewis-Jones","year":"2004","unstructured":"Lewis-Jones, S. Zoonotic poxvirus infections in humans. Curr. Opin. Infect. Dis. 17, 81\u201389 (2004)","journal-title":"Curr. Opin. Infect. Dis."},{"key":"BFnature04295_CR6","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1001\/jama.289.24.3278","volume":"289","author":"JD Grabenstein","year":"2003","unstructured":"Grabenstein, J. D. & Winkenwerder, W. Jr US military smallpox vaccination program experience. J. Am. Med. Assoc. 289, 3278\u20133282 (2003)","journal-title":"J. Am. Med. Assoc."},{"key":"BFnature04295_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/rmv.439","volume":"14","author":"E De Clercq","year":"2004","unstructured":"De Clercq, E. & Neyts, J. Therapeutic potential of nucleoside\/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 14, 289\u2013300 (2004)","journal-title":"Rev. Med. Virol."},{"key":"BFnature04295_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1126\/science.291.5504.585","volume":"291","author":"E Finkel","year":"2001","unstructured":"Finkel, E. Australia. Engineered mouse virus spurs bioweapon fears. Science 291, 585 (2001)","journal-title":"Science"},{"key":"BFnature04295_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.it.2005.04.001","volume":"26","author":"MM Stanford","year":"2005","unstructured":"Stanford, M. M. & McFadden, G. The \u2018supervirus\u2019? Lessons from IL-4-expressing poxviruses. Trends Immunol. 26, 339\u2013345 (2005)","journal-title":"Trends Immunol."},{"key":"BFnature04295_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkh286","volume":"54","author":"M Bray","year":"2004","unstructured":"Bray, M. & Roy, C. J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 54, 1\u20135 (2004)","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnature04295_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","volume":"318","author":"RM Buller","year":"2004","unstructured":"Buller, R. M. et al. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 318, 474\u2013481 (2004)","journal-title":"Virology"},{"key":"BFnature04295_CR12","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1128\/AAC.47.10.3275-3280.2003","volume":"47","author":"DC Quenelle","year":"2003","unstructured":"Quenelle, D. C., Collins, D. J. & Kern, E. R. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob. Agents Chemother. 47, 3275\u20133280 (2003)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature04295_CR13","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1128\/AAC.47.9.2933-2937.2003","volume":"47","author":"CJ Roy","year":"2003","unstructured":"Roy, C. J., Baker, R., Washburn, K. & Bray, M. Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge. Antimicrob. Agents Chemother. 47, 2933\u20132937 (2003)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature04295_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000070618","volume":"49","author":"DF Smee","year":"2003","unstructured":"Smee, D. F., Bailey, K. W. & Sidwell, R. W. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy 49, 126\u2013131 (2003)","journal-title":"Chemotherapy"},{"key":"BFnature04295_CR15","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","volume":"48","author":"J Neyts","year":"2004","unstructured":"Neyts, J., Leyssen, P., Verbeken, E. & De Clercq, E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48, 2267\u20132273 (2004)","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnature04295_CR16","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1086\/422696","volume":"190","author":"DF Smee","year":"2004","unstructured":"Smee, D. F., Bailey, K. W., Wong, M. H., Wandersee, M. K. & Sidwell, R. W. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190, 1132\u20131139 (2004)","journal-title":"J. Infect. Dis."},{"key":"BFnature04295_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0165-6147(02)02091-6","volume":"23","author":"E De Clercq","year":"2002","unstructured":"De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 23, 456\u2013458 (2002)","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnature04295_CR18","first-page":"172","volume":"4","author":"MS Bronze","year":"2003","unstructured":"Bronze, M. S. & Greenfield, R. A. Therapeutic options for diseases due to potential viral agents of bioterrorism. Curr. Opin. Investig. Drugs 4, 172\u2013178 (2003)","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnature04295_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1568005053174627","volume":"5","author":"MN Prichard","year":"2005","unstructured":"Prichard, M. N. & Kern, E. R. Orthopoxvirus targets for the development of antiviral therapies. Curr. Drug Targets Infect. Disord. 5, 17\u201328 (2005)","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"BFnature04295_CR20","first-page":"1","volume":"52","author":"M Wharton","year":"2003","unstructured":"Wharton, M. et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52, 1\u201316 (2003)","journal-title":"MMWR Recomm. Rep."},{"key":"BFnature04295_CR21","doi-asserted-by":"publisher","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","volume":"79","author":"G Yang","year":"2005","unstructured":"Yang, G. et al. An orally bioavailable anti-poxvirus compound (ST-246) that inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79, 13139\u201313149 (2005)","journal-title":"J. Virol."},{"key":"BFnature04295_CR22","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nm1265","volume":"11","author":"PM Reeves","year":"2005","unstructured":"Reeves, P. M. et al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nature Med. 11, 731\u2013739 (2005)","journal-title":"Nature Med."},{"key":"BFnature04295_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1172\/JCI200523220","volume":"115","author":"H Yang","year":"2005","unstructured":"Yang, H. et al. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 115, 379\u2013387 (2005)","journal-title":"J. Clin. Invest."},{"key":"BFnature04295_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nm0705-711","volume":"11","author":"G McFadden","year":"2005","unstructured":"McFadden, G. Gleevec casts a pox on poxviruses. Nature Med. 11, 711\u2013712 (2005)","journal-title":"Nature Med."},{"key":"BFnature04295_CR25","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1081\/NCN-200027573","volume":"23","author":"J Balzarini","year":"2004","unstructured":"Balzarini, J. et al. 6-[2-phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 23, 1321\u20131327 (2004)","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"BFnature04295_CR26","first-page":"109","volume":"62","author":"J Neyts","year":"2004","unstructured":"Neyts, J., Leyssen, P., De Clercq, E. & Holy, A. Effects of (S)-HPMPDAP and (S)-HPMPO-DAPym on vaccinia virus infections in mice. Antiviral Res. 62, 109 (2004)","journal-title":"Antiviral Res."},{"key":"BFnature04295_CR27","first-page":"99","volume":"110","author":"SR Rosenthal","year":"2002","unstructured":"Rosenthal, S. R. & Clifford, J. C. Development of vaccines for bio-warfare agents. Dev. Biol. (Basel) 110, 99\u2013105 (2002)","journal-title":"Dev. Biol. (Basel)"},{"key":"BFnature04295_CR28","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1086\/378357","volume":"188","author":"MS Massoudi","year":"2003","unstructured":"Massoudi, M. S., Barker, L. & Schwartz, B. Effectiveness of postexposure vaccination for the prevention of smallpox: results of a delphi analysis. J. Infect. Dis. 188, 973\u2013976 (2003)","journal-title":"J. Infect. Dis."},{"key":"BFnature04295_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"KC Cundy","year":"1999","unstructured":"Cundy, K. C. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36, 127\u2013143 (1999)","journal-title":"Clin. Pharmacokinet."},{"key":"BFnature04295_CR30","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1128\/JCM.40.8.2919-2921.2002","volume":"40","author":"H Meyer","year":"2002","unstructured":"Meyer, H. et al. Outbreaks of disease suspected of being due to human monkeypox virus infection in the Democratic Republic of Congo in 2001. J. Clin. Microbiol. 40, 2919\u20132921 (2002)","journal-title":"J. Clin. Microbiol."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature04295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature04295","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature04295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T13:20:18Z","timestamp":1684848018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature04295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,11]]},"references-count":30,"journal-issue":{"issue":"7077","published-print":{"date-parts":[[2006,2,9]]}},"alternative-id":["BFnature04295"],"URL":"https:\/\/doi.org\/10.1038\/nature04295","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4053.461545","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,11]]},"assertion":[{"value":"10 September 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Department of Virology and ViroClinics BV are involved in performing monkeypox virus challenge experiments for Bavarian Nordic GmbH (Martinsried, Germany), supported by the National Institutes of Health (NIH).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}